Skip to Content

Tiludronate Side Effects

Applies to tiludronate: oral tablet

General

The most frequently occurring adverse reactions reported were: Diarrhea (9.3%), nausea (9.3%), and dyspepsia (5.3%).[Ref]

Cardiovascular

Common (1% to 10%): Hypertension, flushing[Ref]

Dermatologic

Common (1% to 10%): Rash, skin disorder, pruritus, increased sweating[Ref]

Endocrine

Common (1% to 10%): Hyperparathyroidism[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea, nausea, dyspepsia, vomiting, flatulence, tooth disorder, abdominal pain, constipation, dry mouth gastritis[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection[Ref]

Metabolic

Common (1% to 10%): Vitamin D deficiency, anorexia[Ref]

Musculoskeletal

Bone, joint, and/or muscle pain, rarely severe and/or incapacitating have been reported.[Ref]

Common (1% to 10%): Arthralgia, back pain, arthrosis, fracture pathological, skeletal pain

Postmarketing reports: Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, including this drug[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness, paresthesia, vertigo, involuntary muscle contractions, somnolence, nervousness[Ref]

Ocular

Common (1% to 10%): Cataract, conjunctivitis, glaucoma[Ref]

Other

Common (1% to 10%): Pain, accidental injury, influenza like symptoms, chest pain, peripheral edema, infection, asthenia, syncope, fatigue[Ref]

Psychiatric

Common (1% to 10%): Insomnia, anxiety[Ref]

Respiratory

Common (1% to 10%): Rhinitis, sinusitis, upper respiratory tract infection, coughing, pharyngitis, bronchitis[Ref]

Hypersensitivity

Rare (less than 0.1%): Stevens-Johnson syndrome[Ref]

References

1. Cerner Multum, Inc. "Australian Product Information." O 0

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

3. Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998): 779-89

4. "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY.

5. Roux C, Listrat V, Villette B, Lessana-Leibowitch M, Ethgen D, Pelissier C, Dougados M, Amor B "Long-lasting dermatological lesions after tiludronate therapy." Calcif Tissue Int 50 (1992): 378-80

6. Reginster JY, Lecart MP, Deroisy R, Ethgen D, Zegels B, Franchimont P "Paget's disease of bone treated with a five day course of oral tiludronate." Ann Rheum Dis 52 (1993): 54-7

7. Fraser WD, Stamp TC, Creek RA, Sawyer JP, Picot C "A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone." Postgrad Med J 73 (1997): 496-502

More about tiludronate

Consumer resources

Other brands
Skelid

Professional resources

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.